The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Table 3

Association between DNA repair polymorphisms and platinum-based chemotherapy prognosis.

PFS/OS	Gene	Polymorphism	Genotype	MST (year)	Additive		Dominant		Recessive
					OR (95% CI)		OR (95% CI)		OR (95% CI)
PFS	RPA1	rs5030740	CC	3.72	0.67 (0.40-1.13)	0.136	0.76 (0.43-1.34)	0.341	0.08 (0.01-0.83)	0.034
			CT	3.28
			TT	3.07
OS	EXO1	rs1776148	AA	6.96	0.44 (0.25-0.77)	0.004	0.48 (0.23-0.99)	0.048
			AG	4.34
			GG	4.20
	EXO1	rs1047840	AA	5.43	0.67 (0.37-1.20)	0.177	0.80 (0.39-1.66)	0.551	0.24 (0.07-0.82)	0.023
			AG	4.66
			GG	3.89

MST: median survival time. Additive model: comparison between minor allele subjects and major allele subjects. Dominant model: comparison between minor allele carriers and major homozygous subjects. Recessive model: comparison between major allele carriers and minor homozygous subjects. .